Asia Pacific Radiation Oncology Market: Market Size & Forecast 2026

Radiation oncology in Asia Pacific encompasses linear accelerators (LINACs), brachytherapy systems, treatment planning software, and a growing fleet of proton and carbon-ion facilities serving a population that accounts for more than half of global cancer cases. The regional market is currently valued at around $2.38 billion in 2025, with medical LINACs alone representing roughly $1.29 billion of that base. Growth is significantly outpacing the global radiotherapy average, reflecting both catch-up investment in lower-income countries and ongoing technology replacement in higher-income markets.

• •Estimated 2025 market value: approximately $2.38 billion across all radiation oncology modalities.
• •Medical LINAC sub-segment alone is around $1.29 billion, growing at a mid-single-digit CAGR.
• •Asia Pacific holds a disproportionate share of global cancer cases but historically has had lower radiotherapy capacity per million people than North America or Western Europe.

Rising cancer incidence linked to aging populations, urbanization, and lifestyle changes is the primary volume driver, with breast, lung, head and neck, prostate, and cervical cancers representing the largest treatment pools. Governments across the region are funding radiotherapy expansion to close documented access gaps, and private hospital chains are installing advanced LINACs and proton systems to capture rising middle-class demand. At the same time, technology upgrades from 3D conformal to IMRT, IGRT, VMAT, and adaptive radiotherapy are increasing the value per patient and pulling more capital spending into the sector.

• •Cancer burden: Asia Pacific accounts for roughly half of new global cancer cases, with particularly high volumes of lung, head and neck, breast, and cervical cancers.
• •Access gap: Recent country-level studies show radiotherapy availability remains well below optimal in most low- and middle-income Asia Pacific economies, signaling significant unmet demand.
• •Technology refresh: Replacement of older cobalt-60 and basic LINAC units with image-guided and adaptive systems is accelerating per-unit pricing.

By therapy type, external beam radiation therapy (EBRT) is the largest and fastest-growing segment, while internal beam brachytherapy is widely used for gynecological and prostate cancers. Application is dominated by breast, lung, head and neck, and prostate cancers, with cervical cancer particularly important in South and Southeast Asia. Geographically, China, Japan, India, South Korea, and Australia are the leading national markets, while Southeast Asian economies such as Indonesia, Vietnam, Thailand, and the Philippines represent the fastest-growing frontier as private healthcare investment expands.

• •Therapy split: EBRT leads the market, with internal beam brachytherapy and proton therapy representing smaller but strategically important niches.
• •Application mix: Breast, lung, head and neck, and prostate cancers are the four leading indications, together driving the majority of treatment courses.
• •Country leaders: Japan and China have the largest installed bases; India and Southeast Asia are the highest-growth geographies for new installations.

What are the recent trends and outlook?

The most visible trend is the build-out of proton and carbon-ion therapy centers, with Japan, China, and South Korea leading capacity and additional projects underway in India, Singapore, and Australia. Hypofractionated and stereotactic body radiotherapy (SBRT) protocols are shortening treatment courses, increasing patient throughput per machine, and supporting the region's high cancer volumes. AI-based treatment planning, adaptive radiotherapy, and remote dosimetry services are also scaling rapidly, helping hospitals in lower-resource settings adopt more advanced techniques without proportionally increasing specialist staffing.

• •Particle therapy expansion: New proton and carbon-ion centers are opening across China, Japan, South Korea, India, and Southeast Asia through 2030.
• •AI and adaptive radiotherapy: Adoption of AI-assisted contouring, planning, and online adaptive treatment is accelerating across both public and private centers.
• •Outlook: At an ~11.6% CAGR, the Asia Pacific market is on track to roughly double by the early 2030s, with proton therapy and AI-enabled LINAC systems representing the highest-growth sub-segments.